Academic literature on the topic 'Bureau Veritas'

The innovative paradigm developed by Bureau Veritas has been applied to achieve superior outcomes and benefits for a major oil and gas player. The focus of this innovative approach achieved operational security and risk management for the critical ageing assets. The paradigm and its vital components will become the benchmark for the management and improvement of the performance of ageing assets and serve as a fundamental input to new generation design for oil and gas facilities. Among the key challenges in managing the performance (risk and integrity) of new and ageing assets are the understanding of process safety and critical equipment condition. When discussing with senior management the issues foremost on their minds, Bureau Veritas has found the answer is a common theme—how can I be confident the design of new or existing facilities is fit-for-purpose for the duration of the asset’s life? The integrated approach has brought together the leading concepts/tools in process risk management and prognostic health and reliability engineering. These components include rigorous risk-assessments of the process as well as sensing design based on failure mode consequence effect analysis (FMCEA), data acquisition and processing (real-time monitoring and data fusion), diagnostic and prognostic models and systems for the effective management asset(s). The result of this approach creates a value proposition of financial significance advantage.

In this paper, Bureau Veritas explains the new international regulations on air pollution, its origin, and its position in the marine market to help and develop several technical solutions suitable to the world’s fleet.

The process of digitalization in our society is undeniable and unstoppable and ships are adapting more and more to this new environment. This offers great advantages, since ships can send/receive all the information on all aspects of their current status (allowing more efficient management during the ship's life and even opening the door to autonomous navigation), but this presents a number of intrinsic difficulties due to their connected state (cybersecurity). All the above will be developed with a massive sensorization of the ships, which will indicate their condition, going from a reactive maintenance to a predictive maintenance. This requires the figure of the digital twin, which digitally represents the physical reality of the ship, and which will be a single source of information for all actors. This digital twin opens the door to "Digital Classification" by Bureau Veritas, in which traditional 2D plans are no longer necessary, but work is done directly in 3D on the Digital Twin. Bureau Veritas, as a reference classification society, has adapted to the current situation of the industry, favoring the digitalization process in all its aspects. The objective of this article is to present the current state and foreseeable evolution of the technology leading to the Digital Twin concept, its implications in the design and maintenance of ships, all from the point of view of a Classification Society while exemplifying the digitalization process of a Classification Society in different aspects.

The article presents generally selected issues regarding the safety of ship structures, fuel containment systems, processing and preparation of LNG liquefied gas as fuel for marine propulsion systems and generating sets, in relation to certain requirements of the IGF Code and the provisions of the classification society Bureau Veritas rules. The publication presents the fundamental criteria and assumptions of the IGF Code, which may be taken into account when creating the concept and design of units powered by LNG fuel, also considering the limits of air pollution emissions from ships defined in Annex VI of the MARPOL Convention.

Introduction: Ultrasound (US) assessment of joints is an evolving point of care tool for the detection of early joint arthropathy (Napolitano M, Kessler CM. Hemophilia A and B. Consultative Hemostasis and Thrombosis, Kitchens, 4th edition); population pharmacokinetic (pop-PK) studies are adopted as a useful instrument to set the prophylaxis regimen for patients with hemophilia, they may improve adherence (Nagao A.et al. Thromb Res. 2019 Jan; 173:79-84) and reduce the annual bleeding rate (ABR). Adherence to continuous intravenous administrations of factor VIII or Factor IX products is challenging, thus patients may experience breakthrough bleedings while on prophylaxis. Repeated US examinations of joint status have recently been advocated to attempt to remedy sub-optimal medication adherence (Di Minno A et al., Blood Rev. 2019 Jan;33:106-116). Aim of the current prospective analysis was to evaluate the impact of combined US assessment and pop-PK study on adherence to treatment and health related quality of life in patients with severe hemophilia A(HA) and B (HB) under regular prophylaxis. Material and methods: This prospective observational study was performed at a single tertiary center from January 2017 to June 2019. Research was conducted following the Helsinki Declaration. All patients included in the study provided a written informed consent for study participation. Patients with severe HA and HB routinely underwent, as part of regular 12-months follow-up visits, the following: US joints evaluation of elbows, knees and ankles using the HEAD-US protocol, treatment adherence evaluation by VERITAS-Pro questionnaire, health -related quality of life assessment by the standardized EQ-5D,EQ-VAS and pop-PK study (WAPPS-Hemo, McMaster University) as needed (i.e.in case of changes in life style, planned treatment switch); each patient visualised US and his estimated PK profile during medial encounters. Compliance to the prescribed treatment was also determined by analysis of patient diaries with infusion logs. Statistical analysis was performed using the SPSS software version 25.0 (SPSS Chicago, IL). Statistical tests were 2-sided, with a significance threshold of 0.05. Results: Twenty consecutive males with severe haemophilia were included in the current analysis, 13 with severe HA, 2 with HA with previous inhibitors and 5 HB, with a median age of 30 (range 14- 56) years and a median ABR of 5 (range:0-12). Nine patients were under primary prophylaxis, 8 under secondary prophylaxis and 3 under tertiary prophylaxis, they all self-infused at home. Four patients had one target joint and 3 patients had multiple target joints. For each enrolled subject, HEAD-US score, VERITAS-pro, EQ5D and EQ-VAS score were assessed at enrolment (T0) and at 12 (T12) and 24 (T24) months follow-up visits, respectively. Pop-PK was assessed in 11 patients: in 7 (5 HA,2 HB) it was assessed twice, before and after treatment switch to extended half-life (EHL) products, in 4 it was assessed once to modify prophylaxis treatment schedules for a more active life-style (N=2) or weight changes (N=2). Median ABR was 4 at T12 and 3.8 at T24. Reported breakthrough bleeds at T12 were 14, mainly trauma-related (N= 8) or affecting target joints (N=4), they were not reported at T24 in patients with PK-driven modified schedules (N=4) and in 4 patients under EHL treatments. Mean HEAD-US score at T0 resulted 8 (range:0-16), at T24 it was 6 (range:0-16). Mean Veritas-Pro score values were 42.7 at TO, 40.1 at T12 and 38.7 at T24. At T0, EQ-5D mean utility score was 0.82 (range: 0.68-1), at T24, the mean was 0.87 (range:0.72-1). In detail, at 24 months follow-up, there was a statistically significant (p<0.05) improvement in adherence to treatment with particular reference to the dimensions of communication and skipped doses. A tendency toward improved HEAD-US score, higher adherence and better quality of life scores, was observed in particular in patients switched to EHL products at T24, at a mean of 10 months after switching (range: 6-22 months). Conclusion: Several combined measures of haemophilia treatment monitoring, allowing visual assessment of joints status and PK profile estimates by patients have here shown to improve treatment adherence and quality of life in patients with HA and HB, this may be not only related to new available treatments but also to an increased awareness and education of patients. Disclosures Napolitano: BIOFVIIIx: Consultancy; Novonordisk: Consultancy, Speakers Bureau; Shire: Other: Expert Testimony, Speakers Bureau; Kedrion: Other: Expert Testimony, Speakers Bureau; Octapharma: Speakers Bureau; Bayer: Consultancy, Other: Expert Testimony. Di Minno:Novo Nordisk: Speakers Bureau; CSL: Speakers Bureau; Sanofi: Speakers Bureau; Bayer: Consultancy, Honoraria, Speakers Bureau; Kedrion: Speakers Bureau; Pfizer: Speakers Bureau.

Currently, as a result of new communications technologies, autonomous ships are even closer to our seas than we could think. But, besides un-doubted advantages, it gives rise to uncertainties and challenges in several aspects, which include those related to the fields of cybersecurity and legislation, in relation to international regulations and national laws. The aspects of autonomous shipping are included in the information regulations of Bureau Veritas, and additional specific tags have been created to collect the cybersecurity/cyberprotection aspects of such ships. The objective of this article is to present the current status and the foreseeable evolution of the regulations on autonomous shipping from the point of view of a Classification Society, as well as the current evolution of the methodologies concerning cybersecurity.

Fixed-duration treatment with venetoclax (Ven), a highly selective Bcl-2 inhibitor combined with an anti-CD20 monoclonal antibody, showed high efficacy inducing high rates of deep responses with undetectable minimal residual disease (uMRD) in patients with previously treated and untreated chronic lymphocytic leukemia (CLL). The efficacy and safety of the Ven and rituximab (VenR) combination have been investigated in a multicenter, prospective study of the GIMEMA group that included young patients with previously untreated CLL (LLC 1518, VERITAS, NCT03455517). The primary endpoint of this study was the CR rate assessed according to the iwCLL criteria. Inclusion criteria were: treatment requirement per iwCLL criteria, age ≤65 years, cumulative Illness rating scale score ≤6, creatinine clearance ≥30 mL/min, and an unfavorable biologic profile with IGHV unmutated and or TP53 disruption. Treatment consisted of the Ven dose ramp-up (from 20 to 400 mg daily, during 5-weeks) followed by Ven 400 mg daily, combined with R for six 28-day courses (375 mg/m2, course 1; 500 mg/m2, courses 2-6). Patients continued with Ven single agent, 400 mg daily, until month 13. Tumor lysis syndrome (TLS) prophylaxis measures included hydration, allopurinol, or rasburicase. All patients received PneumocystisJirovecii prophylaxis. G-CSF was given in patients with recurrent and severe granulocytopenia. Adverse events (AEs) were graded according to the CTCAE criteria v.5, TLS events were classified according to Howard's criteria. Response was assessed at months 7 and 15 and included clinical examination, PB evaluation, BM aspirate, BM biopsy, and CT scan. MRD was checked centrally in the PB and BM by a 6/4-color flow-cytometry assay with a sensitivity of at least 10-4 according to the internationally standardized European Research Initiative on CLL. Quantitative MRD results assessed by flow-cytometry were categorized as uMRD (uMRD4; <10-4), intermediate MRD, or high MRD (≥10-2). MRD was further evaluated by allele-specific oligonucleotide PCR with a sensitivity up to 10-5 in the PB and BM of patients who showed uMRD4 by flow-cytometry. During the follow-up, MRD was monitored every 6 months. Between October 2018 and May 2020, 77 patients with CLL were included in this study. Two patients were off study before the start of treatment (withdrawal of consent, 1; Covid-19 infection, 1) and were not included in the analysis. The median age was 53.5 years (range 38-65). Binet stage B/C was present in 84% of patients, increased beta-2 microglobulin in 41%. Seventy-one (96%) of patients were IGHV unmutated, while 3 (4%) were IGHV mutated and showed TP53 mutation (Table 1). At the data cutoff of June 30, 2020, 65 (87%) patients completed the ramp-up phase. The planned 400 mg dose of Ven was reached within 5 weeks in 78.5% of patients. Response was assessed in 34 patients at the end of the VenR combination therapy. A response was achieved by 32 (94%) patients. Responses included 20 (59%) CRs, 1 CRi (3%) and 11 (32%) PRs due to residual enlarged nodes (median maximum size, 1.9 cm). Treatment failure due to toxicity was recorded in 2 (6%) patients. Overall, a response with uMRD4 by flow-cytometry in the PB was observed in 26 (76.5%) cases, and in the PB and BM, in 17 (50.0%). The rates of patients with CR and uMRD4 by flow-cytometry in the PB, and both in the PB and BM, were 44%, and 35%, respectively (Table 2). No detectable disease by PCR, both in the PB and BM, was observed in 4 (12%) patients. With a median follow-up of 4.5 months from the start of therapy, no patient has progressed or died. Fifty-three percent of patients were hospitalized during the first seven days of the Ven ramp-up phase. A transient laboratory TLS was observed in 3 patients. Treatment was discontinued after the first dose of Ven in 1 patient with evidence of laboratory TLS associated with severe neurologic toxicity due to the concomitant administration of fentanyl. Selected grade ≥3 AEs included neutropenia in 10 patients (ramp-up phase, 5) and neutropenic fever in 4. Grade ≥3 infection was recorded in 3 patients and was the reason for treatment discontinuation in 1 who developed COVID-19 pneumonia. In conclusion, the preliminary results of this study demonstrate the high efficacy of the front-line VenR combination, which resulted in a high proportion of CRs and responses with uMRD4 in young patients with CLL and an unfavorable biologic profile. Disclosures Mauro: Astrazeneca: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jannsen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Octopharma: Consultancy. Reda:Gilead: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees. Trentin:Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Shire: Honoraria; Takeda: Membership on an entity's Board of Directors or advisory committees; Octapharma: Membership on an entity's Board of Directors or advisory committees. Coscia:Shire: Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees; Karyopharm Therapeutics: Research Funding; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Sportoletti:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Laurenti:Roche: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Gaidano:Astrazeneca: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sunesys: Membership on an entity's Board of Directors or advisory committees. Marasca:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Honoraria; Roche: Membership on an entity's Board of Directors or advisory committees. Murru:Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Rigolin:Gilead: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Scarfo:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AstraZeneca: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees. Marchetti:Pfizer: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees; Amgen: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees. Levato:Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Galieni:Celgene: Honoraria; Takeda: Honoraria; AbbVie: Honoraria; Janssen: Honoraria. Liberati:Verastem: Research Funding; Onconova: Research Funding; Janssen: Honoraria, Research Funding; Roche: Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Honoraria, Research Funding; Pfizer: Research Funding; Karyopharm: Research Funding; Morphosys: Research Funding; Novartis: Research Funding; GSK: Research Funding; Incyte: Honoraria; Oncopeptides: Research Funding; Takeda: Research Funding. Molica:Roche: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Visentin:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Vitale:Janssen: Honoraria. Del Giudice:Janssen: Other: grant for meeting participation; Tolero: Membership on an entity's Board of Directors or advisory committees; Roche: Other: grant for meeting partecipation; AstraZeneca: Membership on an entity's Board of Directors or advisory committees. Cuneo:Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astra Zeneca: Honoraria; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Foà:Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Incyte: Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees; Novartis: Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees.

El presente trabajo de investigación se ha identificado una oportunidad de negocio en el sector Agrario referido específicamente a los análisis de residuos de pesticidas que se realizan a todos los productos agrícolas que se producen en el Perú con fines de exportación como son: quinua, kiwicha, palta, arándano, uva, espárragos, alcachofas, pimientos etc.; productos que se producen y exportan en grandes volúmenes a diferentes mercados del mundo con exigencias especificas principalmente en la parte de contaminantes como son los remanentes de pesticidas. Las empresas exportadoras del sector agrícola no están satisfechas con el servicio de análisis de residuos de pesticidas que ofrecen otras empresas del mercado, debido a ello se evidencia que existe una oportunidad de negocio referido a los análisis de residuos de pesticidas orientado al segmento productor, comercializador y exportador de productos agrícolas. Esto ha sido validado con un estudio de mercado orientado al segmento objetivo en donde se ha obtenido como resultado que el 85% del total de empresas encuestadas aceptaría el servicio de análisis de residuos de pesticidas con Bureau Veritas. En consecuencia de esta oportunidad se ha planteado implementar una nueva línea de servicio de análisis de residuos de pesticidas en Bureau Veritas que se basa en bridar un servicio de análisis de residuos de pesticidas diferenciado en calidad y tiempo. Este servicio se inicia desde el recojo e ingreso de las muestras al laboratorio de forma oportuna, usando inspectores locales o courier existentes en cada zona; además se brindara resultados de ensayos en menores tiempos que el mercado actual ofrece. Para ello se adquirirá equipos de tecnología de punta de mayor sensibilidad en la detección de los residuos de pesticida en función de los límites máximos residuales (LMRs) exigidos por los mercados destinos. El modelo de negocio establecido brindará lo siguiente: • Atención directa y personalizada con los ejecutivos comerciales para las cotizaciones del servicio en forma oportuna. • Recojo oportuno de muestras y envío al laboratorio, mediante los inspectores zonales y couriers locales. • Atención directa y personalizada por un ejecutivo de cuenta (Key account), quien será el único responsable de realizar el seguimiento del ingreso, ejecución y envío del resultado del análisis, manteniendo la trazabilidad de las muestras. • Garantizar un análisis de calidad mediante la adquisición de nuevos equipos con tecnología de punta en análisis de residuos de pesticidas, tales como el HPLC MS-MS (Cromatografía Liquida de Alta performance) y el GC MS-MS (Cromatografía Gaseosa de alta performance). • Entrega inmediata del resultado de ensayo a través de una plataforma virtual que permite al cliente el acceso en línea a los resultados. • Brindar precios escalonados en función al volumen de muestras a analizar. Para implementar este nuevo servicio se requiere de una inversión inicial de S/. 1, 311,538 que serán solventadas mediante un préstamo y leasing. Como resultado de esta inversión se proyecta un incremento en la generación de ingresos de ventas para la División de Agri & Foods de Bureau Veritas, obteniendo como indicadores financieros un VAN S/. 483,242.49 y una TIR 19.31% ejecutado en un periodo de 5 años. Por lo expuesto se concluye que el servicio de análisis de residuos de pesticidas ofrecido por Bureau Veritas está avalado por la aceptación de las empresas del segmento agrícola y los indicadores financieros obtenidos.
The present research work has identified a business opportunity in the agrarian sector, specifically referred to the analysis of pesticide residues that are made to all agrarian sector products which are produced in Peru for export purposes, such as: quinoa, kiwicha, avocado, cranberry, grape, asparagus, artichokes, peppers etc; these products are produced and exported in big amounts to different markets in the world. These products exported must accomplish with specifics requirements of contaminants such as the remnants of pesticides. Because of the export companies of the agricultural sector are not satisfied about the analysis service of pesticide residues offered by other companies, there is a business opportunity related to pesticide residue analysis oriented to producer segment, marketer and exporter of agricultural products. This business opportunity has been validated throught a market study referred at the target segment which it has been obtained as result that 85% of all companies surveyed, so they would accept to Bureau Veritas such as a supplier for analysis service of pesticide residues. As a result of this business opportunity, this reseach propose to implement a new service line in Bureau Veritas for analysis of pesticide residues, in this way, it will have better features about quality and delivery respect to all current companies. This new service starts since the sample is collected, shortly carried and deposited in time at the laboratory, it could done by local inspectors or couriers. In addition, the test results will be deliveried in shorter times than the current market offers, in this way, this test result will be supported by high technology equipments acquired with high sensivity detecting pesticide residues according to limits maximun residuals (LMRs) required by the destination markets. The established business model will provide the following: • Direct and personal attention through the commercial executives to give the quotations of the service in time. • Timely collection of samples and sending to the laboratory, through zonal inspectors and local couriers. • Direct and personalized attention by an account executive, who will be the sole responsible for tracking the entry, execution and delivery of the result of the analysis, maintaining the traceability of the samples. • Guarantee a quality analysis through new high technology equipment in pesticide residue analysis, such as HPLC MS-MS (High Performance Liquid Chromatography) and GC MS-MS (Gas Chromatography high performance). • Immediate delivery of the test result through a virtual platform that allows to the customer to access on line to see the results. • Provide prices quotation according to the amount of samples to be analyzed. To implement this new service is necessary to do an initial investment of S /. 1, 311,538 that they will be paid through a loan and leasing. As a result of this investment it is projected an increase in sales for the Agri & Foods Division of Bureau Veritas, obtaining as financial indicators a VAN S /. 483,242.49 and one IRR 19.31% executed in a period of 5 years. In conclusion, the new service of pesticide residue analysis to offer by Bureau Veritas is supported by the acceptance of the companies of the agricultural segment and the financial indicators obtained.
Trabajo de investigación

Over the years, new regulations, safety and environmental concerns from the public have emphasized the requirement for pipeline owners to demonstrate and document the safe operation of their facilities. In Europe, the “Seveso 2” regulation has mentioned pipelines in the requirement for safety and integrity management of hazardous facilities. What were originally technical issues related to inspection and maintenance have now been wrapped up in the general concept of pipeline integrity management. The safety of pipelines has indeed become a social accountability issue at Corporate level for every Operator. Bureau Veritas has been involved since its inception in the conformity assessment, the certification of facilities and organisations and has developed a vast experience in the field of QHSE and Regulatory compliance. Based on this experience, Bureau Veritas is developing a practical approach to Pipeline Integrity Management, providing guidelines and methodologies for operators. The paper describes a performance-based and risk-based approach to Pipeline Integrity Management. The approach includes: assessment of the condition of facilities (through audits and inspections), performing risk analysis and engineering criticality assessments, drawing up the priority list of further inspections, interventions, repairs and maintenance, assisting and advising in the selection of the appropriate methodologies and tools, controlling the execution of such inline inspections, cathodic protection surveys, safety systems upgrades, maintenance and repair works. Bureau Veritas has also developed calculation criteria to interpret inspection data and to advise on fitness for service of the facilities to prioritize the repair works.

In general, petroleum reservoirs vary with geographical locations and their environmental conditions, and there are no crude and gas exactly alike in respective locations. This means that it is very difficult to apply a specific standard design, which is usually preferred by many shipyards, to any FPSO hull. These facts often lead to serious trouble for FPSO hull construction in terms of cost and delivery time. In order to solve those challenging issues, Mitsui E&S Shipbuilding Co., Ltd. developed a next generation FPSO platform, “noah-FPSO Hull” (noah : New Offshore Adapted Hull), and obtained Approval in Principle for the noah-FPSO Hull from two world leading classification societies, Bureau Veritas and American Bureau of Shipping. Unique modular design and multi-yard construction concept of the noah-FPSO Hull were overviewed and discussed in our 1st report [1]. This paper is the 2nd report of the noah-FPSO Hull and focuses on discussing specific modular design for structural design and equipment arrangement. Hull motion in adverse weather condition is also discussed.

It is often said that every offshore oil field has its own environmental condition and oil property according to its geographical location. This means that it is very difficult to apply a specific standard design to any FPSO hull, which is usually preferred by many shipyards. This fact often leads to serious trouble for FPSO hull construction in terms of cost and delivery time. In order to cope with this problem, Mitsui Engineering and Shipbuilding Co., Ltd. (MES) developed a next generation offshore platform for FPSO, “Mitsui noah-FPSO Hull” (noah : New Offshore Adapted Hull), which consists of unique modular design and construction concept and simple hull form. Structural design is also modularized, i.e. common cross section and frame space, will facilitate to standardized topside module design. In fact, it can be constructed even in multi-shipyards as a consistent cross-platform. MES has obtained Approval In Principle (AIP) for the noah-FPSO Hull design and concept from American Bureau of Shipping (ABS) and Bureau Veritas (BV). In this paper, MES introduces these modular concept of the noah-FPSO Hull and its developed technical issues.

In late 2001 classification societies Lloyd’s Register, the American Bureau of Shipping and Det Norske Veritas (LR, ABS and DNV) announced plans to standardize a wide number of mutually agreed upon initiatives covering survey and engineering. This standardization process was precipitated as a response to calls for more robust requirements as well as a Class response to calls for improvement made by governments, industry and the general public. One of the initiatives was the establishment of a joint tanker project team (JTP) to develop Common Structural Rules for Tankers so that competition on structural requirements (safety) would be eliminated. Once the common rules are finalized and in effect, they will replace the current tanker rules of LR, ABS and DNV. This paper outlines the rule development process, key technical aspects of the common rules, the impact to the design scantlings, and future maintenance of these rules.

This paper presents a methodology to take into account model uncertainties related to the load-end shortening curve of stiffened panels. This method is a part of a research activity carried out at University of Liege. His goal is to propose a reliability based model to assess hull girder ultimate strength using a progressive collapse algorithm. The numerical results presented here concern the load-shortening model chosen for this research, which is based on Bureau Veritas rules. Model uncertainty is quantified as a parameter considered as a random variable. Four statistical moments (mean, standard deviation, skewness and kurtosis) of this parameter are calculated and analyzed using a data-base of stiffened panels test results published in recent years. In order to increase the number of “actual” values for the statistical assessment, the data-base is completed with non-linear finite element analysis results. The paper contains also some recommendation for the implementation of the proposed method in ultimate strength reliability based analysis.

The paper describes the way a large pre-stressed concrete Floating Production Unit (FPU) located offshore Congo on N’KOSSA field has been inspected and assessed in order to meet both Bureau Veritas Class and Floating Units Integrity Management System (FUIMS) requirements. This FPU is the largest existing pre-stressed concrete barge. She was built with high performance concrete, installed offshore in 1996 in 170 m water depth. She has now accumulated 18 years of production. A significant part of the methodology is based on close inspection for the concrete structure, a graphic assessment of the defects and an implementation of monitoring. This assessment is done a long time after construction and we had to cope with difficulties relative to the structure size, loss of data, barge in operations off-shore. It gives a good feedback of what we should implement during the design and the construction to keep a clear view of the concrete barge integrity.

The present paper is related to the verification of unbonded flexible pipes designed and manufactured as per API 17J [1]. Back in the early nineties, in response to the needs of the industry for better quality, reliability and safety in unbonded flexible pipe products, Bureau Veritas established an innovative verification scheme relying not only on qualification testing, but also on the assessment of design methods, materials as well as manufacturing processes. This approach has proven particularly relevant considering several specificities of the flexible pipe industry: no ‘on-the-shelf’ design (each pipe being designed for project specific conditions), manufacturer specific local design methodologies, specific materials and manufacturing methods, high complexity and cost of testing. This paper presents the verification methodology, its application as well as its ability to embody the latest normative requirements given in [1]. The specificity of the verification scheme, which consists in a breakdown between a Type Approval phase and a project phase, is also presented.

Tidal turbines are emerging technologies offering a great potential by the harnessing of a renewable and predictable resource. However, exploitation at sea comes with significant design, installation, grid connection, and maintenance operations challenges. Consequently, guidelines and standards are required to ensure safety, reliability and quality for these innovative technologies, to support designers and to accelerate the development and commercialisation of the tidal technology. As tidal energy concepts are only at the demonstration stage, only few standards have been published about tidal and current turbines and no dedicated certification procedures have been developed so far. The aim of this paper is to present a risk-based certification process developed by Bureau Veritas for tidal turbines and published in the Guidance Note NI603 Current and Tidal Turbines. Based on experience accumulated over the past years with tidal turbines technology developers, typical challenges related to the design and installation of tidal devices at sea will be highlighted in this paper. To support tidal turbines designers to take up these challenges, Bureau Veritas provides a decision-making guide gathering 1) recommendations from the existing experience at sea of tidal devices, 2) best practices from related sectors, such as shipping, wind energy or offshore oil & gas, 3) a risk-based approach to consider for the particular requirements of each tidal turbine installation. In particular for tidal turbines, projects are highly site specific with huge impacts on farm layouts and foundation designs, to name but a few of the issues to be addressed. Paradoxically, the aim of certification societies is to develop rules and tools that can be applicable to a wide range of designs. Consequently, trying not to be design-specific, a proposal of a generic certification process is made in this paper. Existing certification principles from more mature sectors such as wind energy, offshore oil & gas or shipping have been adapted to the specificities of tidal turbines. This paper addresses different certification procedures such as prototype certification, component certification, type certification and project certification. Their respective application and interactions are developed, with a focus on prototype and type certification. In addition, particular attention is paid to the novelty induced by tidal turbines. Consequently, a risk-based guidance is provided to use qualification of new technology for the most innovative parts of the tidal device.

Tidal turbines are emerging technologies offering great potential for the harnessing of a renewable and predictable oceanic resource. However, exploitation at sea comes with significant design, installation, grid connection, and maintenance operations challenges. Consequently, guidelines and standards are required to ensure safety, quality, performance and accelerate tidal turbines development and commercialisation. Standardisation is also a necessity to support and improve safety and confidence of a wide range of Marine Renewable Energy (MRE) stakeholders such as designers, project operators, investors, insurers or final users. There are undergoing developments on guidelines, standards and certification systems within the International Electrotechnical Commission (IEC) Technical Committee TC 114 “Marine energy - Wave, tidal and other water current converters” and the IEC Renewable Energy “Marine Energy - Operational Management Committee” (IECRE ME – OMC). However, as the tidal energy concepts are only at the demonstration stage, only few guidelines and no dedicated certification scheme has been published so far within this organization, which guarantee an international, independent, non-governmental and consensus-based elaboration process. The aim of this paper is to present a proposal of certification methodology, developed by Bureau Veritas for the design assessment of current and tidal turbines, and its application to a French case study. This certification procedure was developed within the French research project Sabella D10 funded by ADEME and is published in the Bureau Veritas guideline NI603 “Current & Tidal Turbines”. The suggested certification procedure addresses prototype, component, type and project certification. Main objective, scope, intermediary steps to be completed and resulting certificates will be detailed for each certification scheme, as well as their interactions. This methodology will be illustrated by the case study on the Sabella D10 prototype, a French tidal turbine installed in 2015 in the Fromveur Passage, off Ushant Island. Sabella D10 is a 1 MW tidal turbine fully submerged laid on the seabed with a horizontal axis and 6 blades. It is the first French tidal turbine producing electricity and connected to the electrical network. The Sabella D10 case study will focus on prototype certification and computations performed for support structure and blades. The paper will describe the load cases that have been considered, the review procedure for the support structure and the blades design assessment, including description of a streamlined method for basic design and a detailed method for final design. In conclusion, the next steps will be introduced to continue the certification developments of tidal and current turbines.

Abstract The generation and propagation of waves in a viscous flow solver are indispensable part of naval computational fluid dynamic (CFD) applications. This paper presents numerical simulations of two-dimensional wave propagation in the framework of two-phase finite volume method (FVM) with different temporal discretization schemes. Implicit Euler, Crank-Nicolson (CN) and second-order backward temporal discretization schemes are compared by using viscous flow solver based on the open source library OpenFOAM. The combinations of each temporal discretization scheme and explicit limiter are used for the formulation of the Volume Of Fluid (VOF) field convection equation. A new formulation using the second-order backward temporal discretization scheme with explicit limiter are investigated. Two-dimensional periodic domains are considered to compare different time-stepping methods. Also, five different refinement levels of meshes are used to study the convergence properties of each method. The non-linear wave is generated with stream function wave theory using ‘foamStar’, which is a specialized OpenFOAM library package developed by Bureau Veritas in collaboration with École Centrale de Nantes.